Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia
1 other identifier
observational
50
1 country
1
Brief Summary
Iron overload is well study in Thalassemia patients and it's not only related to blood transfusions, since intestinal iron absorption is also increased in those patients. Sickle cell patients didn't developed significant clinical symptoms and signs of iron overload in spite frequent transfusions. The purpose of this study is to assess the iron overload in Sickle cell anemia and Sickle cell Thalassemia patients using clinical parameters and laboratory studies including Non Transferrin Binding Iron, Labile Iron and Hepcidin, in order to determine the cardiac and liver iron.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 5, 2007
CompletedFirst Posted
Study publicly available on registry
August 7, 2007
CompletedStudy Start
First participant enrolled
September 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2010
CompletedAugust 26, 2011
August 1, 2011
2.2 years
August 5, 2007
August 25, 2011
Conditions
Keywords
Study Arms (1)
1
Patients suffering from Sickle cell disease
Interventions
Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
Eligibility Criteria
All tha patinets suffering from Sickle cell disease trreated at the Pediatric Hematology Unit
You may qualify if:
- All the patients with Sickle Cell Anemia and Sickle Cell Thalassemia that are treated and followed up at the Pediatric Hematology Unit.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Pediatric Hematology Unit - HaEmek Medical Center
Afula, Afula, 18101, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ariel Koren, MD
Pediatric Hematology Unit, Ha'Emek Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Pediatric Hematology Unit and Pediatric Dpt B
Study Record Dates
First Submitted
August 5, 2007
First Posted
August 7, 2007
Study Start
September 1, 2008
Primary Completion
December 1, 2010
Study Completion
December 1, 2010
Last Updated
August 26, 2011
Record last verified: 2011-08